ATLAS fair value
ATLAS has no fair value for this stock today.
Jiangsu GDK Biotechnology stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Shanghai Stock Exchange · China
Prices as of Oct 27, 2026 · CNY
ATLAS has no fair value for this stock today.
46%
that it ends higher than today in 21 sessions
ATLAS's own quantitative analysis, all in one place.
Plans from €3.99 a month.
ATLAS's model gives Jiangsu GDK Biotechnology a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between CN¥11.01 and CN¥14.14; in 9 out of 10, between CN¥8.83 and CN¥17.64. Estimated annual volatility is 75%.
ATLAS does not publish a fair value for 688670.SHG right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 688670.SHG has traded between CN¥12.32 and CN¥31.20. Today it is 59.4% below that high and 3% above its low.
Its beta is 0.31: it tends to move less than the market.
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines.
Want to see everything about Jiangsu GDK Biotechnology?
Get started →Plans from €3.99 a month.
Other companies in the same line of business:
Jiangsu Gdk Biological Technology Co., Ltd engages in the research, development, production, and sale of human vaccines. It offers quadrivalent influenza virus split vaccines.
46%: close to a coin flip. In half of the simulated outcomes, 688670.SHG ends the month between CN¥11.01 and CN¥14.14.
Jiangsu GDK Biotechnology's market capitalization is CN¥1.7B. We do not show a P/E because it has no positive earnings to base one on.
ATLAS estimates annual volatility at 75%. In a typical month, half of the outcomes end between CN¥11.01 and CN¥14.14.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer
ATLAS Signals
The week in the market, three stocks on ATLAS’s radar and what comes next. Get it every Monday.
By subscribing you agree to receive ATLAS Signals by email every Monday. You can unsubscribe with one click at any time. Privacy